全文获取类型
收费全文 | 2326篇 |
免费 | 233篇 |
国内免费 | 6篇 |
专业分类
2565篇 |
出版年
2023年 | 12篇 |
2022年 | 30篇 |
2021年 | 44篇 |
2020年 | 21篇 |
2019年 | 24篇 |
2018年 | 42篇 |
2017年 | 34篇 |
2016年 | 66篇 |
2015年 | 97篇 |
2014年 | 100篇 |
2013年 | 115篇 |
2012年 | 185篇 |
2011年 | 165篇 |
2010年 | 114篇 |
2009年 | 115篇 |
2008年 | 114篇 |
2007年 | 120篇 |
2006年 | 81篇 |
2005年 | 77篇 |
2004年 | 96篇 |
2003年 | 76篇 |
2002年 | 65篇 |
2001年 | 81篇 |
2000年 | 65篇 |
1999年 | 59篇 |
1998年 | 21篇 |
1997年 | 22篇 |
1996年 | 18篇 |
1995年 | 11篇 |
1994年 | 14篇 |
1993年 | 17篇 |
1992年 | 41篇 |
1991年 | 27篇 |
1990年 | 28篇 |
1989年 | 43篇 |
1988年 | 30篇 |
1987年 | 28篇 |
1986年 | 14篇 |
1985年 | 26篇 |
1984年 | 20篇 |
1983年 | 14篇 |
1982年 | 15篇 |
1981年 | 15篇 |
1980年 | 22篇 |
1979年 | 35篇 |
1978年 | 20篇 |
1977年 | 10篇 |
1976年 | 11篇 |
1974年 | 24篇 |
1973年 | 14篇 |
排序方式: 共有2565条查询结果,搜索用时 15 毫秒
91.
Summary Kadazans, the largest indigenous group in Sabah, northern Borneo, were surveyed for glyoxalase I, phosphoglucomutase I, red cell acid phosphatase, esterase D, adenosine deaminase, soluble glutamate pyruvate transaminase, soluble glutamate oxaloacetate transaminase, 6-phosphogluconate dehydrogenase, uridine monophosphate kinase, adenylate kinase, peptidase B and D, superoxide dismutase, C5, group specific component, haptoglobin and transferrin.Kadazans were found to be polymorphic for GLOI, PGMI, RCAP, esterase D, ADA, s-Gpt, 6PGD, UMPK, Gc, C5, haptoglobin and peptidase B. Rare variants were found for transferrin and peptidase D. No variant was found for s-Got, SOD and AK. 相似文献
92.
93.
Lawrence C. M. Lau Li Ma Alvin L. Young Shi Song Rong Vishal Jhanji Marten E. Brelen Chi Pui Pang Li Jia Chen 《PloS one》2014,9(10)
Topic
A meta-analysis of TCF4 and PTPRG gene variants in Fuchs'' corneal dystrophy (FCD).Clinical relevance
To identify novel genetic markers in patients with FCD in different ethnic populations.Methods
MEDLINE and EMBASE were searched for eligible genetic studies on TCF4 and PTPRG in FCD. Odds ratios (OR) and 95% confidence intervals (CI) of each single-nucleotide polymorphism (SNP) in allelic, dominant and recessive models were estimated using fixed-effect model if I2<50% in the test for heterogeneity, otherwise the random effects model was used.Results
Thirty-three records were obtained, with 8 being suitable for meta-analysis, which included five SNPs in TCF4 and two in PTPRG. There were 1610 FCD patients and 1565 controls tested for TCF4 rs613872. This SNP was strongly associated with FCD in Caucasians (P = 5.0×10−106), with the risk allele G conferring an OR of 3.95 (95% CI: 3.49–4.46). A further 4 TCF4 SNPs (rs17595731, rs2286812, rs618869 and rs9954153) were also significantly associated with FCD in Caucasians (P<10−8). However, we found no SNP associated with FCD in Chinese. In addition, there was no significant association between FCD and PTPRG.Conclusion
TCF4 rs613872 is strongly associated with FCD in Caucasians but not in Chinese, which may suggest ethnic diversity in FCD SNP associations. SNPs in PTPRG were not associated with FCD in Caucasians or Chinese populations. Results of this meta-analysis indicate the need for larger-scale and multi-ethnic genetic studies on FCD to further explore the associated gene variants and their roles on the mechanism and genetic basis of FCD. 相似文献94.
Degradation of cyclin A does not require its phosphorylation by CDC2 and cyclin-dependent kinase 2 总被引:8,自引:0,他引:8
Many cyclins are degraded by the ubiquitination/proteasome pathways involving the anaphase-promoting complex and SCF complexes. These degradations are frequently dependent on phosphorylation by cyclin-dependent kinases (CDKs), providing a self-limiting mechanism for CDK activity. Here we present evidence from in vitro and in vivo assay systems that the degradation of human cyclin A can be inhibited by kinase-inactive mutants of CDK2 and CDC2. One obvious interpretation of these results is that like other cyclins, CDK-dependent phosphorylation of the cyclin A may be involved in cyclin A degradation. Our data indicated that CDK2 can phosphorylate cyclin A on Ser-154. Site-directed mutagenesis of Ser-154 abolished the phosphorylation by recombinant CDK2 in vitro and the majority of cyclin A phosphorylation in the cell. Activation of CDK2 and binding to SKP2 or p27(KIP1) were not affected by the phosphorylation of Ser-154. Surprising, in marked contrast to cyclin E, where phosphorylation of Thr-380 by CDK2 is required for proteolysis, degradation of cyclin A was not affected by Ser-154 phosphorylation. It is likely that the stabilization of cyclin A by the kinase-inactive CDKs was mainly due to a cell cycle effect. These data suggest an important difference between the regulation of cyclin A and cyclin E. 相似文献
95.
Amy Li K. Campbell S. Lal Y. Ge A. Keogh P. S. Macdonald P. Lau John Lai W. A. Linke J. Van der Velden A. Field B. Martinac M. Grosser Cristobal dos Remedios 《Biophysical reviews》2022,14(1):369
In this review, we present our current understanding of peripartum cardiomyopathy (PPCM) based on reports of the incidence, diagnosis and current treatment options. We summarise opinions on whether PPCM is triggered by vascular and/or hormonal causes and examine the influence of comorbidities such as preeclampsia. Two articles published in 2021 strongly support the hypothesis that PPCM may be a familial disease. Using large cohorts of PPCM patients, they summarised the available genomic DNA sequence data that are expressed in human cardiomyocytes. While PPCM is considered a disease predominately affecting the left ventricle, there are data to suggest that some cases also involve right ventricular failure. Finally, we conclude that there is sufficient evidence to warrant an RNAseq investigation and that this would be most informative if performed at the cardiomyocytes level rather than analysing genomic DNA from the peripheral circulation. Given the rarity of PPCM, the combined resources of international human heart tissue biobanks have assembled 30 ventricular tissue samples from PPCM patients, and we are actively seeking to enlarge this patient base by collaborating with human heart tissue banks and research laboratories who would like to join this endeavour. 相似文献
96.
97.
98.
99.
Dingge Ying Pak Chung Sham David Keith Smith Lu Zhang Yu Lung Lau Wanling Yang 《Genome biology》2015,16(1)
Recent founder mutations may play important roles in complex diseases and Mendelian disorders. Detecting shared haplotypes that are identical by descent (IBD) could facilitate discovery of these mutations. Several programs address this, but are usually limited to detecting pair-wise shared haplotypes and not providing a comparison of cases and controls. We present a novel algorithm and software package, HaploShare, which detects extended haplotypes that are shared by multiple individuals, and allows comparisons between cases and controls. Testing on simulated and real cases demonstrated significant improvements in detection power and reduction of false positive rate by HaploShare relative to other programs.
Electronic supplementary material
The online version of this article (doi:10.1186/s13059-015-0662-9) contains supplementary material, which is available to authorized users. 相似文献100.
AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei—Crystal structure,mode of action,and biological activity 下载免费PDF全文
Krishnamurthy Narasimha Rao Anirudha Lakshminarasimhan Sarah Joseph Swathi U Lekshmi Ming-Seong Lau Mohammed Takhi Kandepu Sreenivas Sheila Nathan Rohana Yusof Noorsaadah Abd Rahman Murali Ramachandra Thomas Antony Hosahalli Subramanya 《Protein science : a publication of the Protein Society》2015,24(5):832-840
Melioidosis is a tropical bacterial infection caused by Burkholderia pseudomallei (B. pseudomallei; Bpm), a Gram-negative bacterium. Current therapeutic options are largely limited to trimethoprim-sulfamethoxazole and β-lactam drugs, and the treatment duration is about 4 months. Moreover, resistance has been reported to these drugs. Hence, there is a pressing need to develop new antibiotics for Melioidosis. Inhibition of enoyl-ACP reducatase (FabI), a key enzyme in the fatty acid biosynthesis pathway has shown significant promise for antibacterial drug development. FabI has been identified as the major enoyl-ACP reductase present in B. pseudomallei. In this study, we evaluated AFN-1252, a Staphylococcus aureus FabI inhibitor currently in clinical development, for its potential to bind to BpmFabI enzyme and inhibit B. pseudomallei bacterial growth. AFN-1252 stabilized BpmFabI and inhibited the enzyme activity with an IC50 of 9.6 nM. It showed good antibacterial activity against B. pseudomallei R15 strain, isolated from a melioidosis patient (MIC of 2.35 mg/L). X-ray structure of BpmFabI with AFN-1252 was determined at a resolution of 2.3 Å. Complex of BpmFabI with AFN-1252 formed a symmetrical tetrameric structure with one molecule of AFN-1252 bound to each monomeric subunit. The kinetic and thermal melting studies supported the finding that AFN-1252 can bind to BpmFabI independent of cofactor. The structural and mechanistic insights from these studies might help the rational design and development of new FabI inhibitors. 相似文献